Uni-Bio Science Group Full Year 2024 Earnings: EPS: HK$0.013 (vs HK$0.011 in FY 2023)

Uni-Bio Science Group (HKG:690) Full Year 2024 Results

Key Financial Results

• Revenue: HK$553.0m (up 14% from FY 2023).
• Net income: HK$82.8m (up 17% from FY 2023).
• Profit margin: 15% (in line with FY 2023).
• EPS: HK$0.013 (up from HK$0.011 in FY 2023).

We've discovered 1 warning sign about Uni-Bio Science Group. View them for free.

690 Post-Clinical Trial Products

• Pre-registration: 1.
• Launched (during full year): 2.

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the Biological Pharmaceutical Products segment contributing a total revenue of HK$303.4m (55% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to HK$261.6m (69% of total expenses). Explore how 690's revenue and expenses shape its earnings.

Uni-Bio Science Group shares are up 1.5% from a week ago.

Risk Analysis

Before you take the next step you should know about the 1 warning sign for Uni-Bio Science Group that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.